您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Odevixibat
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Odevixibat
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Odevixibat图片
规格:98%
分子量:740.93
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议

产品介绍
Odevixibat (A4250) 是一种有效的选择性回肠胆汁酸转运蛋白 (IBAT) 抑制剂。Odevixibat (A4250) 可减轻小鼠模型中的胆汁淤积性肝和胆管损伤。Odevixibat (A4250)可用于原发性胆汁性肝硬化的研究。
货号:ajcx35066
CAS:501692-44-0
分子式:C37H48N4O8S2
分子量:740.93
溶解度:DMSO : 166.67 mg/mL (224.95 mM; Need ultrasonic)
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Odevixibat (A4250) is a potent, selective and orally active inhibitor of the ileal bile acid transporter (IBAT). Odevixibat (A4250)decreases cholestatic liver and bile duct injury in mice model. Odevixibat (A4250) has the potential for the treatment of primary biliary cirrhosis[1].

Odevixibat (A4250)(0.01% (w/w) in chow diet; 4 weeks) improves sclerosing cholangitis and significantly reduces serum alanine aminotransferase, alkaline phosphatase and BAs levels, hepatic expression of pro-inflammatory and pro-fibrogenic genes and bile duct proliferation in Mdr2-/- mice[1]. In addition, Odevixibat (A4250) significantly reduces bile flow and biliary BA output, which correlates with reduced bsep transcription, while Ntcp and Cyp7a1 are induced[1].

[1]. Baghdasaryan A, et al. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.J Hepatol. 2016 Mar;64(3):674-81.